CVS Health's 2025 'Less Certain' Following 2024 Guidance Withdrawal, Changes in Leadership, RBC Capital Says

MT Newswires Live

Nov 16, 2024

CVS Health's (CVS) 2025 appears "less certain" now that the healthcare company has withdrawn its 2024 guidance and announced changes in leadership, RBC Capital Markets said in a note Friday.

The investment firm said it was lowering its Q4 earnings estimate to $0.75 from $1.66 previously to reflect the company's Q3 results and "persistent utilization headwinds." The Q4 forecast is based on an elevated medical loss ratio, or MLR, estimate of 95.7%, up from 92.1% previously, RBC said.

RBC slashed its 2025 earnings outlook to $5.71 from $7.33 based on a MLR estimate of 92.2%, up from 89.7% earlier.

"With premium deficiency reserves recorded in the quarter, utilization is higher than previously expected, prompting investor concerns around 2025 pricing and utilization," RBC said in its note.

The firm reiterated an outperform rating on the stock and cut its price target to $58 from $68.

Price: 52.97, Change: -2.13, Percent Change: -3.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483847715"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483847715\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483847715?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483847715","market":"fut","top_or_hot":-1,"title":"CVS Health's 2025 'Less Certain' Following 2024 Guidance Withdrawal, Changes in Leadership, RBC Capital Says","media":"MT Newswires Live","content":"<html><body><p> CVS Health's (CVS) 2025 appears \"less certain\" now that the healthcare company has withdrawn its 2024 guidance and announced changes in leadership, RBC Capital Markets said in a note Friday.</p><p>The investment firm said it was lowering its Q4 earnings estimate to $0.75 from $1.66 previously to reflect the company's Q3 results and \"persistent utilization headwinds.\" The Q4 forecast is based on an elevated medical loss ratio, or MLR, estimate of 95.7%, up from 92.1% previously, RBC said.</p><p>RBC slashed its 2025 earnings outlook to $5.71 from $7.33 based on a MLR estimate of 92.2%, up from 89.7% earlier.</p><p>\"With premium deficiency reserves recorded in the quarter, utilization is higher than previously expected, prompting investor concerns around 2025 pricing and utilization,\" RBC said in its note.</p><p>The firm reiterated an outperform rating on the stock and cut its price target to $58 from $68.</p><p>Price: 52.97, Change: -2.13, Percent Change: -3.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health's 2025 'Less Certain' Following 2024 Guidance Withdrawal, Changes in Leadership, RBC Capital Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health's 2025 'Less Certain' Following 2024 Guidance Withdrawal, Changes in Leadership, RBC Capital Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-16 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CVS Health's (CVS) 2025 appears \"less certain\" now that the healthcare company has withdrawn its 2024 guidance and announced changes in leadership, RBC Capital Markets said in a note Friday.</p><p>The investment firm said it was lowering its Q4 earnings estimate to $0.75 from $1.66 previously to reflect the company's Q3 results and \"persistent utilization headwinds.\" The Q4 forecast is based on an elevated medical loss ratio, or MLR, estimate of 95.7%, up from 92.1% previously, RBC said.</p><p>RBC slashed its 2025 earnings outlook to $5.71 from $7.33 based on a MLR estimate of 92.2%, up from 89.7% earlier.</p><p>\"With premium deficiency reserves recorded in the quarter, utilization is higher than previously expected, prompting investor concerns around 2025 pricing and utilization,\" RBC said in its note.</p><p>The firm reiterated an outperform rating on the stock and cut its price target to $58 from $68.</p><p>Price: 52.97, Change: -2.13, Percent Change: -3.86</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1571399168.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483847715","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483847715","pubTimestamp":1731700885,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CVS Health's  2025 appears \"less certain\" now that the healthcare company has withdrawn its 2024 guidance and announced changes in leadership, RBC Capital Markets said in a note Friday.The investment firm said it was lowering its Q4 earnings estimate to $0.75 from $1.66 previously to reflect the company's Q3 results and \"persistent utilization headwinds.\" The Q4 forecast is based on an elevated medical loss ratio, or MLR, estimate of 95.7%, up from 92.1% previously, RBC said.RBC slashed its 2025 earnings outlook to $5.71 from $7.33 based on a MLR estimate of 92.2%, up from 89.7% earlier.\"With premium deficiency reserves recorded in the quarter, utilization is higher than previously expected, prompting investor concerns around 2025 pricing and utilization,\" RBC said in its note.The firm reiterated an outperform rating on the stock and cut its price target to $58 from $68.Price: 52.97, Change: -2.13, Percent Change: -3.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4207":"综合性银行","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4196":"保健护理服务","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4581":"高盛持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","CVS.AU":"Cervantes Corp Ltd","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","CVS":"西维斯健康","BK4585":"ETF&股票定投概念","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4504":"桥水持仓","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4550":"红杉资本持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD"},"translate_title":"加拿大皇家银行资本(RBC Capital)表示，在2024年指导撤回和领导层变动后，CVS Health 2025年“不太确定”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1,"CVS.AU":1},"content_text":"CVS Health's (CVS) 2025 appears \"less certain\" now that the healthcare company has withdrawn its 2024 guidance and announced changes in leadership, RBC Capital Markets said in a note Friday.The investment firm said it was lowering its Q4 earnings estimate to $0.75 from $1.66 previously to reflect the company's Q3 results and \"persistent utilization headwinds.\" The Q4 forecast is based on an elevated medical loss ratio, or MLR, estimate of 95.7%, up from 92.1% previously, RBC said.RBC slashed its 2025 earnings outlook to $5.71 from $7.33 based on a MLR estimate of 92.2%, up from 89.7% earlier.\"With premium deficiency reserves recorded in the quarter, utilization is higher than previously expected, prompting investor concerns around 2025 pricing and utilization,\" RBC said in its note.The firm reiterated an outperform rating on the stock and cut its price target to $58 from $68.Price: 52.97, Change: -2.13, Percent Change: -3.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}